TY - JOUR
T1 - Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus
AU - Amanat, Fatima
AU - Strohmeier, Shirin
AU - Meade, Philip
AU - Dambrauskas, Nicholas
AU - Mühlemann, Barbara
AU - Smith, Derek J.
AU - Vigdorovich, Vladimir
AU - Noah Sather, D.
AU - Coughlan, Lynda
AU - Krammer, Florian
N1 - Publisher Copyright:
Copyright: © 2021 Amanat et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2021/12
Y1 - 2021/12
N2 - AU Vaccines: Pleaseconfirmthatallheadinglevelsarerepresentedcorrectly against Severe Acute Respiratory Syndrome Coronavirus : 2 (SARS-CoV-2) have been highly efficient in protecting against Coronavirus Disease 2019 (COVID-19). However, the emergence of viral variants that are more transmissible and, in some cases, escape from neutralizing antibody responses has raised concerns. Here, we evaluated recombinant protein spike antigens derived from wild-type SARS-CoV-2 and from variants B.1.1.7, B.1.351, and P.1 for their immunogenicity and protective effect in vivo against challenge with wild-type SARS-CoV-2 in the mouse model. All proteins induced high neutralizing antibodies against the respective viruses but also induced high cross-neutralizing antibody responses. The decline in neutralizing titers between variants was moderate, with B.1.1.7vaccinated animals having a maximum fold reduction of 4.8 against B.1.351 virus. P.1 induced the most cross-reactive antibody responses but was also the least immunogenic in terms of homologous neutralization titers. However, all antigens protected from challenge with wild-type SARS-CoV-2 in a mouse model.
AB - AU Vaccines: Pleaseconfirmthatallheadinglevelsarerepresentedcorrectly against Severe Acute Respiratory Syndrome Coronavirus : 2 (SARS-CoV-2) have been highly efficient in protecting against Coronavirus Disease 2019 (COVID-19). However, the emergence of viral variants that are more transmissible and, in some cases, escape from neutralizing antibody responses has raised concerns. Here, we evaluated recombinant protein spike antigens derived from wild-type SARS-CoV-2 and from variants B.1.1.7, B.1.351, and P.1 for their immunogenicity and protective effect in vivo against challenge with wild-type SARS-CoV-2 in the mouse model. All proteins induced high neutralizing antibodies against the respective viruses but also induced high cross-neutralizing antibody responses. The decline in neutralizing titers between variants was moderate, with B.1.1.7vaccinated animals having a maximum fold reduction of 4.8 against B.1.351 virus. P.1 induced the most cross-reactive antibody responses but was also the least immunogenic in terms of homologous neutralization titers. However, all antigens protected from challenge with wild-type SARS-CoV-2 in a mouse model.
UR - http://www.scopus.com/inward/record.url?scp=85122291986&partnerID=8YFLogxK
U2 - 10.1371/journal.pbio.3001384
DO - 10.1371/journal.pbio.3001384
M3 - Article
C2 - 34914685
AN - SCOPUS:85122291986
SN - 1544-9173
VL - 19
JO - PLoS Biology
JF - PLoS Biology
IS - 12
M1 - e3001384
ER -